Agilent Technologies, Inc. (NYSE:A) Upgraded to Strong-Buy by BidaskClub

BidaskClub upgraded shares of Agilent Technologies, Inc. (NYSE:A) from a buy rating to a strong-buy rating in a research note released on Sunday, August 6th.

A has been the subject of a number of other research reports. Deutsche Bank AG reissued a buy rating and set a $66.00 target price on shares of Agilent Technologies in a report on Thursday, June 22nd. Morgan Stanley raised their price target on Agilent Technologies from $65.00 to $70.00 and gave the stock an overweight rating in a research report on Wednesday, May 24th. BTIG Research increased their price objective on Agilent Technologies from $57.00 to $65.00 and gave the company a buy rating in a research note on Wednesday, May 24th. Zacks Investment Research upgraded Agilent Technologies from a hold rating to a buy rating and set a $63.00 price target on the stock in a research note on Tuesday, May 16th. Finally, Cowen and Company lifted their target price on Agilent Technologies from $53.00 to $62.00 and gave the stock a market perform rating in a research report on Tuesday, May 23rd. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $63.18.

Agilent Technologies (NYSE:A) traded up 0.64% during trading on Friday, reaching $61.25. The company’s stock had a trading volume of 2,357,872 shares. Agilent Technologies has a one year low of $42.92 and a one year high of $62.42. The stock has a 50-day moving average of $60.30 and a 200 day moving average of $56.14. The firm has a market capitalization of $19.72 billion, a P/E ratio of 31.59 and a beta of 1.30.

Agilent Technologies (NYSE:A) last announced its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the firm earned $0.49 earnings per share. The business’s revenue was up 6.7% compared to the same quarter last year. On average, equities research analysts predict that Agilent Technologies will post $2.31 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/08/19/agilent-technologies-inc-nysea-upgraded-at-bidaskclub-updated.html.

In other news, CEO Michael R. Mcmullen sold 50,000 shares of the company’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total value of $2,993,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul N. Clark sold 3,866 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $59.05, for a total transaction of $228,287.30. The disclosure for this sale can be found here. In the last 90 days, insiders sold 125,615 shares of company stock worth $7,543,943.

Several large investors have recently modified their holdings of A. BlackRock Inc. raised its stake in Agilent Technologies by 1.2% in the second quarter. BlackRock Inc. now owns 23,392,338 shares of the medical research company’s stock valued at $1,387,400,000 after buying an additional 273,119 shares during the period. Vanguard Group Inc. raised its stake in Agilent Technologies by 3.0% in the second quarter. Vanguard Group Inc. now owns 22,093,669 shares of the medical research company’s stock valued at $1,310,374,000 after buying an additional 637,698 shares during the period. FMR LLC raised its stake in Agilent Technologies by 3.9% in the first quarter. FMR LLC now owns 21,588,407 shares of the medical research company’s stock valued at $1,141,379,000 after buying an additional 803,993 shares during the period. State Street Corp raised its stake in Agilent Technologies by 1.0% in the first quarter. State Street Corp now owns 14,457,425 shares of the medical research company’s stock valued at $764,348,000 after buying an additional 147,518 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Agilent Technologies by 45.2% in the second quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock valued at $720,358,000 after buying an additional 3,779,099 shares during the period.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

What are top analysts saying about Agilent Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agilent Technologies Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit